Skip to main content
Premium Trial:

Request an Annual Quote

PrimeraDx Reels in $20M in Investments

NEW YORK (GenomeWeb News) – The molecular diagnostics firm PrimeraDx has closed $20 million in a Series C financing round through investments from new and existing investors.

This round of investments was led by CHL Medical Partners and included Abingworth, InterWest Partners, Malaysian Technology Development, MPM Capital, Burrill & Company, and the Invus Group.

PrimeraDx CEO and President Martin Verhoef said in a statement that the company will use the funding to continue commercializing its technology, including advancing its regulatory strategy and broadening a quantitative, multiplexed assay menu to run on its ICEPlex system.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.